AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...
Cancer drugs are booming, obesity bets are rising, and a Trump deal just locked in three years of tariff-free growth.
Investor's Business Daily on MSN
AstraZeneca Bounds Into A Chase Zone As Cancer Drugs Drive Sales Beat
AstraZeneca stock bounded into a buy zone Thursday after sales of its cancer drugs beat Wall Street's expectations by about 5 ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access ...
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...
Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive ...
Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...
Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback